Join
Live feed
·
PRReleasevia Quantisnow
Inventiva S.A. logo

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

ByQuantisnow·Wall Street's wire, on your screen.
IVA· Inventiva S.A.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IVA (Inventiva S.A.) and more on Quantisnow.